Initial Therapeutics
PrivateLast Round
Series A
May 1, 2023
Total Funding Raised
$75M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Initial Therapeutics is a biotechnology company that develops small-molecule medicines designed to prevent pathogenic protein synthesis by selectively terminating translation at the ribosome.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Initial Therapeutics Comparables
Compare Initial Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Interdict Bio | 89% | |
| Ribometrix | 79% | |
| Arrakis Therapeutics | 78% |
Initial Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | May 1, 2023 |
Initial Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Apple Tree Partners | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors increased 159% MoM, from 301 to 781.
Initial Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Initial Therapeutics's valuation, stock price, and market status.
Is Initial Therapeutics a public or private company?
Initial Therapeutics is a private company.
What is the current stock price of Initial Therapeutics?
Initial Therapeutics is a private company, so its shares have no public market price. Caplight tracks Initial Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Initial Therapeutics worth (valuation)?
Valuation information for Initial Therapeutics is not publicly available.
Can I buy Initial Therapeutics stock?
Initial Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Initial Therapeutics's last funding round?
Initial Therapeutics's most recent funding round was Series A on May 1, 2023.
Who are the main investors in Initial Therapeutics?
Key investors in Initial Therapeutics include Apple Tree Partners.
Will Initial Therapeutics IPO soon?
No public IPO plans have been announced for Initial Therapeutics.
How can I track Initial Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Initial Therapeutics's shares on secondary markets.